Lead Product(s) : Dexfenfluramine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Immunophotonics | AngioDynamics
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 08, 2024
Lead Product(s) : Dexfenfluramine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Immunophotonics | AngioDynamics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexfenfluramine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2023
Lead Product(s) : Dexfenfluramine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexfenfluramine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Immunophotonics
Deal Size : Inapplicable
Deal Type : Inapplicable
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2019
Lead Product(s) : Dexfenfluramine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Immunophotonics
Deal Size : Inapplicable
Deal Type : Inapplicable